Novartis AG expressed confidence its nAMD eye treatment RTH258 (brolucizumab) would be approved and become a blockbuster after it released further positive Phase III data comparing the novel anti-VEGF treatment to Eylea, using lower dosing which nonetheless showed superiority in key retinal health outcomes.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?